REVIEW ARTICLE |
|
Year : 2015 | Volume
: 4
| Issue : 1 | Page : 3-8 |
|
Therapeutic strategies for multiple sclerosis: Current data
Anastasios M Georgiou
University of Sheffield, Medical School, Sheffield Institute of Translational Neuroscience, Sheffield, United Kingdom
Correspondence Address:
Anastasios M Georgiou James Cook University, Division of Tropical Health and Medicine, Rehabilitation & Exercise Science Building 43, Room 137, Townsville, QLD 4811 United Kingdom
Source of Support: None, Conflict of Interest: None | Check |
DOI: 10.4103/2278-344X.149199
|
|
At present, the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved drugs for Relapsing Remitting Multiple Sclerosis (RRMS) and Secondary Progressive MS (SPMS). In this paper, modern therapeutic strategies for MS are reviewed. A comprehensive research in MEDLINE, PUBMED, and SCIENCEDIRECT databases using two Boolean phrases {i.e. 1. [(Multiple Sclerosis) and (Disease Modifying Therapies)] and 2. [(Multiple Sclerosis) and (Neuroprotective Therapies)]} yielded more than 1,5000 articles in total. Therefore, for the purposes of this paper, articles written within the last decade were considered for review. |
|
|
|
[FULL TEXT] [PDF]* |
|
|
|